US Pharma MarketingRQ Bio secures $115m to develop influenza antibody programme
RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups. RQ Bio’s lead asset, RQB01, is currently in IND-enabling studies. RQ Bio CEO Mike Westby. Credit: RQ Bio/GlobeNewswire. UK-based RQ Bio has closed a £85.5m ($115m) Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups. Frazier Life Sciences led the financing round along with new investors EQT Life Sciences, Forbion, Monograph and Wellington Management. LOA and PTSR Model MRNA-1083 in…
RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.
Source: Pharmaceutical Technology